Sugi Predict

Sugi Predict / Compounds / SCHEMBL2066248

SCHEMBL2066248

SCHEMBL2066248

NC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GJA1 P17302 1/20 0.38
▸ GJB2 P29033 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LGALS1 P09382 2/20 0.38
▸ LGALS3 P17931 2/20 0.38
▸ LGALS9 O00182 1/20 0.38
▸ LGALS8 O00214 1/20 0.38
▸ IDUA P35475 1/20 0.36
▸ LRAT O95237 1/20 0.36
▸ CA2 P00918 4/20 0.34
▸ CA12 O43570 3/20 0.34
▸ CA1 P00915 3/20 0.34
▸ CA9 Q16790 3/20 0.34
▸ HOGA1 Q86XE5 1/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13857459 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL15753514 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL12361504 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL14088638 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL12809623 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL23517631 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL2066246 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL10059606 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL21001789 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR
SCHEMBL12015074 1.00 GJA1 (0.38) GJA1GJB2MEN1CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118078995-A Dual-targeting high-water-solubility micromolecular boron drug as well as preparation method and application thereof 东莞市人民医院 2024-05-28 — — CN claimed
EP-0320960-B1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1993-05-12 — — EP claimed
US-5145848-A AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1992-09-08 — — US claimed
EP-0396588-A1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1990-11-14 — — EP claimed
WO-1989005815-A1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1989-06-29 — — WO claimed
EP-0320960-A1 Amino anthracenediones-bis platinum complexes, useful as antitumoral agents BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1989-06-21 — — EP claimed
CN-118078995-B Dual-targeting high-water-solubility micromolecular boron drug as well as preparation method and application thereof 东莞市人民医院 2024-08-23 — — CN disclosed
CN-118078995-A Dual-targeting high-water-solubility micromolecular boron drug as well as preparation method and application thereof 东莞市人民医院 2024-05-28 — — CN disclosed
US-8148321-B2 Bioconjugates as therapeutic agent and synthesis thereof NATIONAL INSTITUTE OF IMMUNOLOGY (US) 2012-04-03 — — US disclosed
US-20090088372-A1 Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof NATIONAL INSTITUTE OF IMMUNOLOGY (IN) 2009-04-02 — — US disclosed
EP-1996236-A2 NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF National Institute of Immunology (IN) 2008-12-03 — — EP disclosed
WO-2007108013-A2 NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF NATIONAL INSTITUTE OF IMMUNOLOGY (IN) 2007-09-27 — — WO disclosed
US-20070042030-A1 Preparation for the application of agents in mini-droplets IDEA AG (DE) 2007-02-22 — — US disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 — — WO disclosed
EP-0396588-A1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1990-11-14 — — EP disclosed
WO-1989005815-A1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1989-06-29 — — WO disclosed
EP-0320960-A1 Amino anthracenediones-bis platinum complexes, useful as antitumoral agents BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1989-06-21 — — EP disclosed
EP-0186085-A2 Platinum complexes AMERICAN CYANAMID COMPANY (US) 1986-07-02 — — EP disclosed
US-4587331-A ANTITUMOR AMERICAN CYANAMID COMPANY (US) 1986-05-06 — — US disclosed
US-4156777-A FROM AN AMINO-GLUCOPYRANOSE AND O-NITRO OR -CYANO-PHENYL N-SUBSTITUTED-N-NITROSOCARBAMATE; ANTITUMOR AGENTS TOKYO TANABE COMPANY, LIMITED (JP) 1979-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088372-A1 Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof DNPEP, LNPEP, RNPEP GJA1 4785/4885GJB2 4834/4885MEN1 3589/4885
US-20070042030-A1 Preparation for the application of agents in mini-droplets FABP4, NPC1L1, LIPA GJA1 2063/4885GJB2 2671/4885MEN1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.